One Stem Cell, 14 Million Cancer Killers

A Breakthrough in Supply

Chinese scientists have devised a way to mass-produce powerful cancer-fighting immune cells from a single stem cell — a development that could reshape the economics of cancer immunotherapy worldwide. A team led by Prof. Wang Jinyong at the Institute of Zoology, Chinese Academy of Sciences, published the findings in Nature Biomedical Engineering, describing a scalable method that generates up to 14 million natural killer (NK) cells from a single blood stem cell.

Why NK Cells Matter

Natural killer cells are a frontline weapon of the immune system, capable of detecting and destroying malignant cells without prior sensitization. For decades, researchers have sought to harness them for cancer treatment — but supply has remained a crippling bottleneck. Isolating mature NK cells from blood or tissue is laborious, expensive, and yields quantities far too small for widespread therapeutic use. Conventional NK therapies are burdened by high variability, low engineering efficiency, elevated costs, and time-intensive processing — barriers that have kept the approach largely out of reach for most patients.

The Three-Step Method

Rather than harvesting mature NK cells, the Chinese team works with CD34+ hematopoietic stem and progenitor cells (HSPCs) extracted from umbilical cord blood. A three-stage protocol then takes over:

• Expansion: Stem cells multiply 800- to 1,000-fold over 14 days on specialized feeder cells
• Commitment: Cells are guided into the NK lineage using artificial hematopoietic organoid structures
• Maturation: Final cells develop the surface markers and tumor-killing machinery needed for clinical use

The process can also produce CAR-iNK cells — versions equipped with chimeric antigen receptors engineered to home in on specific cancer proteins — yielding 7.6 million such cells per starting stem cell.

Numbers That Change the Equation

A single CD34+ stem cell can produce up to 14 million iNK cells, according to ScienceDaily. Scaled up, one-fifth of a standard cord blood unit could theoretically supply thousands of individual therapeutic doses. The cost reduction is equally striking: by engineering cells at the stem cell stage rather than at maturity, the process requires only 1/140,000 to 1/600,000 of the viral vector load normally needed — directly cutting one of the largest expense drivers in cell therapy manufacturing.

From Lab to Clinic

In mouse models of B-cell acute lymphoblastic leukemia, the CAR-iNK cells successfully suppressed tumor growth and extended survival, providing proof-of-concept for clinical application. The broader NK immunotherapy field is already advancing: several CAR-NK therapies are in Phase III trials targeting blood cancers. NK cells also carry a structural advantage over CAR-T therapies — they can be sourced from healthy donors or cord blood banks and potentially administered as off-the-shelf treatments, avoiding the expensive, patient-specific manufacturing that defines T-cell therapies. Solid tumors remain a harder challenge, with most NK trials still in early phases, but the scalability problem has long been the primary obstacle to progress.

Democratizing Cancer Care

Advanced immunotherapy has long been the preserve of patients at elite medical centers in high-income countries. By slashing production costs and dramatically increasing yield, the Chinese team's innovation could bring effective NK cell therapy within reach for far more patients globally — a meaningful step toward making cutting-edge cancer immunotherapy a mainstream treatment rather than a privilege of the few.